Fasting-Mimicking Diet Shows Promise for Crohn's Disease: What the New Trial Found

What Is a Fasting-Mimicking Diet and How Does It Help Crohn's Disease?

The fasting-mimicking diet (FMD) was originally developed by Valter Longo, a professor of gerontology and biological sciences at the University of Southern California. Unlike a full water fast, the FMD provides a carefully calibrated low-calorie, low-protein, plant-based meal plan over five consecutive days, designed to trigger the body's fasting pathways — including autophagy and immune cell regeneration — while reducing the risks and difficulty associated with complete food restriction.

In Crohn's disease, the immune system mistakenly attacks the lining of the gastrointestinal tract, causing chronic inflammation, pain, diarrhea, and fatigue. Current treatments focus primarily on suppressing the immune response with medications such as biologics and immunomodulators. However, dietary interventions have remained frustratingly elusive, with no consensus on what Crohn's patients should eat. The new clinical trial suggests that periodic cycles of the FMD may help calm intestinal inflammation and improve quality of life, offering a non-pharmacological tool that could complement existing therapies.

What Did the Clinical Trial Find About Symptom Relief?

According to the trial findings reported in 2026, patients with mild to moderate Crohn's disease who completed cycles of the five-day fasting-mimicking diet showed improvements in clinical symptom scores and reductions in inflammatory biomarkers such as C-reactive protein. Participants reported feeling better relatively quickly, with some noting symptom relief after just the first cycle. The diet appeared to be well-tolerated, though researchers emphasized that patients followed the protocol under medical supervision.

The mechanism behind these benefits likely involves the diet's ability to reduce pro-inflammatory immune cells and promote regeneration of the intestinal lining. Previous preclinical work by Longo's group, published in Cell Reports, had shown that fasting-mimicking cycles could reduce intestinal inflammation and promote stem cell–driven tissue repair in mouse models of inflammatory bowel disease. The new human trial represents a critical step in translating those laboratory findings into clinical practice, though researchers caution that larger, longer-term trials are needed before the approach can be broadly recommended.

Should Crohn's Patients Try This Diet on Their Own?

While the trial results are encouraging, gastroenterologists urge caution. Crohn's disease patients are often at risk of malnutrition, nutrient deficiencies, and unintended weight loss, which means any form of caloric restriction must be carefully monitored. The fasting-mimicking diet used in the trial was a specific, medically supervised protocol — not simply eating less for five days. Attempting an unsupervised version could worsen nutritional status or trigger a disease flare.

The Crohn's and Colitis Foundation notes that dietary management of inflammatory bowel disease remains highly individualized, and what works for one patient may not work for another. The new research adds an important piece to the puzzle, but it does not replace standard medical treatment. Patients interested in exploring dietary approaches should discuss options with their gastroenterologist, who can help assess whether a supervised fasting-mimicking protocol might be appropriate alongside their current treatment plan.